- Thiogenesis Therapeutics Corp. (TTI) has granted a total of 450,000 incentive stock options to sundry officers
- The company embarked on that in line with its stock option plan, of which 350,000 were granted to directors and officers and 100,000 to a consultant
- Each option entitles the optionee to acquire one common share of the company at an exercise price of $0.60 per common share until December 8, 2032
- Thiogenesis Therapeutics, Corp. is a clinical-stage biopharmaceutical company operating through its wholly-owned subsidiary based in San Diego, CA
- Thiogenesis Therapeutics Corp. was unchanged at C$0.60 at 12:04 PM ET
Thiogenesis Therapeutics Corp. (TTI) has granted a total of 450,000 incentive stock options to sundry officers.
The company embarked on that in line with its stock option plan, of which 350,000 were granted to directors and officers and 100,000 to a consultant.
Each option entitles the optionee to acquire one common share of the company at an exercise price of $0.60 per common share until December 8, 2032.
The options vest in quarterly instalments starting June 30, 2023, and become fully vested by December 31, 2024.
The options are exercisable for a ten-year term, expiring December 8, 2032.
Thiogenesis Therapeutics Corp. is a clinical-stage biopharmaceutical company operating through its wholly-owned subsidiary based in San Diego, CA. Thiogenesis is developing sulfur-containing prodrugs that act as precursors to thiol-active compounds, with the potential to treat serious pediatric diseases with unmet medical needs.
Thiogenesis Therapeutics Corp. was unchanged at C$0.60 at 12:04 PM ET.